{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:45:22Z","timestamp":1789429522870,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012324","name":"University Hospitals of Cleveland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.eprac.2023.03.004","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:44:37Z","timestamp":1679445877000},"page":"566-571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Statin Intolerance: A Review and Update"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-6032","authenticated-orcid":false,"given":"Yumiko","family":"Tsushima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5285-5858","authenticated-orcid":false,"given":"Betul","family":"Hatipoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2023.03.004_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.eprac.2023.03.004_bib2","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"10.1016\/j.eprac.2023.03.004_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient","volume":"16","author":"Cheeley","year":"2022","journal-title":"J\u00a0Clin Lipidol"},{"issue":"34","key":"10.1016\/j.eprac.2023.03.004_bib4","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.eprac.2023.03.004_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"10.1016\/j.eprac.2023.03.004_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacl.2019.04.011","article-title":"The Statin Adverse Treatment Experience survey: experience of patients reporting side effects of statin therapy","volume":"13","author":"Jacobson","year":"2019","journal-title":"J\u00a0Clin Lipidol"},{"issue":"12","key":"10.1016\/j.eprac.2023.03.004_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.36802","article-title":"Statin discontinuation and cardiovascular events among older people in Denmark","volume":"4","author":"Thompson","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"43","key":"10.1016\/j.eprac.2023.03.004_bib8","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1093\/eurheartj\/ehz458","article-title":"Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France","volume":"40","author":"Giral","year":"2019","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.eprac.2023.03.004_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40256-021-00492-8","article-title":"Association between vitamin d and statin-related myopathy: a meta-analysis","volume":"22","author":"Hou","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"issue":"9","key":"10.1016\/j.eprac.2023.03.004_bib10","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1185\/03007995.2011.598144","article-title":"Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance","volume":"27","author":"Glueck","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"19","key":"10.1016\/j.eprac.2023.03.004_bib11","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: an updated meta-analysis of randomized controlled trials","volume":"7","author":"Qu","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.eprac.2023.03.004_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.006","article-title":"Effect of coenzyme Q10 on statin-associated myalgia and adherence to statin therapy: a systematic review and meta-analysis","volume":"299","author":"Kennedy","year":"2020","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.eprac.2023.03.004_bib13","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"issue":"7","key":"10.1016\/j.eprac.2023.03.004_bib14","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/pds.977","article-title":"Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy","volume":"13","author":"Chang","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"10.1016\/j.eprac.2023.03.004_bib15","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0002-9149(02)02355-X","article-title":"The liver and lovastatin","volume":"89","author":"Tolman","year":"2002","journal-title":"Am J Cardiol"},{"issue":"25","key":"10.1016\/j.eprac.2023.03.004_bib16","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1016\/j.jacc.2021.04.075","article-title":"Effect of statin therapy on cognitive decline and incident dementia in older adults","volume":"77","author":"Zhou","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.eprac.2023.03.004_bib17","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1038\/s41598-018-24248-8","article-title":"Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta-analysis","volume":"8","author":"Chu","year":"2018","journal-title":"Sci Rep"},{"issue":"24","key":"10.1016\/j.eprac.2023.03.004_bib18","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.eprac.2023.03.004_bib19","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association Of Clinical Endocrinologists And American College Of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr Pract"},{"issue":"17","key":"10.1016\/j.eprac.2023.03.004_bib20","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.eprac.2023.03.004_bib21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2003.02044.x","article-title":"Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems","volume":"57","author":"Sinzinger","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.eprac.2023.03.004_bib23","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.amjcard.2015.08.011","article-title":"Incident diabetes mellitus, hypertension, and cardiovascular disease risk in exercising hypercholesterolemic patients","volume":"116","author":"Williams","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.eprac.2023.03.004_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104719","article-title":"Statin therapy in athletes and patients performing regular intense exercise - Position paper from the International Lipid Expert Panel (ILEP)","volume":"155","author":"Katsiki","year":"2020","journal-title":"Pharmacol Res"},{"issue":"6","key":"10.1016\/j.eprac.2023.03.004_bib25","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"issue":"23","key":"10.1016\/j.eprac.2023.03.004_bib26","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a Monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.eprac.2023.03.004_bib27","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 Antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.eprac.2023.03.004_bib28","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.eprac.2023.03.004_bib29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.metabol.2008.09.019","article-title":"Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?","volume":"58","author":"Glueck","year":"2009","journal-title":"Metabolism"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23000678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X23000678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:14:30Z","timestamp":1761516870000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X23000678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1530891X23000678"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2023.03.004","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin Intolerance: A Review and Update","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2023.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}